Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded research grants to investigators following a review of proposals submitted in response to the NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4-million research grant from GlaxoSmithKline to scientifically evaluate and define clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212) in treatment of advanced mela...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news